Sharks give a handle to potent anti-tumor multiparatopic antibodies inducing membrane depletion of PD-L1
{{output}}
Despite the immense clinical success of the antibody therapeutics that neutralize programmed death receptor ligand 1 (PD-L1) and thus resurrect T cell antitumor activity, the patient response rates remain low. In this issue of Cell Chemical Biology, Ludwig et ... ...
